Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) SVP Andrew Davis Sells 5,360 Shares

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) SVP Andrew Davis sold 5,360 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.08, for a total transaction of $21,868.80. Following the sale, the senior vice president now directly owns 284,685 shares in the company, valued at $1,161,514.80. The trade was a 1.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Ironwood Pharmaceuticals Stock Up 3.0 %

NASDAQ IRWD opened at $3.44 on Friday. Ironwood Pharmaceuticals, Inc. has a one year low of $3.26 and a one year high of $15.70. The business has a 50 day simple moving average of $4.23 and a 200 day simple moving average of $5.36.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.07). The company had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business’s revenue was down 19.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.12 EPS. On average, equities analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Institutional Trading of Ironwood Pharmaceuticals

Several large investors have recently made changes to their positions in IRWD. KBC Group NV boosted its holdings in Ironwood Pharmaceuticals by 59.3% in the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 3,198 shares in the last quarter. CWM LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 2,345 shares in the last quarter. Wolverine Trading LLC acquired a new stake in Ironwood Pharmaceuticals in the 3rd quarter valued at $51,000. Diversified Trust Co bought a new stake in Ironwood Pharmaceuticals during the 3rd quarter valued at $52,000. Finally, Legacy Capital Group California Inc. acquired a new position in Ironwood Pharmaceuticals during the third quarter worth $59,000.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on IRWD shares. StockNews.com downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Craig Hallum decreased their price target on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Capital One Financial lowered Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. Wells Fargo & Company decreased their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. Finally, Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $10.40.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.